IgG4-related disease – treatment with anti-CD20, anti-CD19 antibodies, and other new drugs
Authors:
prof. MUDr. Adam Zdeněk, CSc. 1; prof. MUDr. Doubek Michael, Ph.D. 1; doc. MUDr. Řehák Zdeněk, Ph.D. 2; doc. MUDr. Zbořil Vladimír, CSc. 3; MUDr. Kubeš Václav, Ph.D. 4; Mgr. Borský Marek 1; MUDr. Adamová Zuzana, Ph.D. 5,6; MUDr. Čermák Aleš, Ph.D. 7; MUDr. König Jiří 8; MUDr. Boichuk Ivanna 1; MUDr. Štork Martin, Ph.D. 1; prof. MUDr. Pour Luděk, Ph.D. 1
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno
1; Oddělení nukleární medicíny, MOÚ, Brno
2; Interní gastroenterologická klinika LF MU a FN Brno
3; Ústav patologie, LF MU a FN Brno
4; Chirurgické oddělení, Moravskoslezská nemocnice Frýdek-Místek, p. o.
5; Chirurgické oddělení, Vsetínská nemocnice a. s
6; Urologická klinika LF MU a FN Brno
7; Oddělení ORL, FN Brno
8
Published in:
Klin Onkol 2026; 39(4): 238-254
Category:
Review
doi:
https://doi.org/10.48095/ccko2026238
Overview
Background: IgG4-related disease (IgG4-RD) can affect any tissue. Characteristic symptoms include tumor-like swelling of one or more organs, lymphadenopathy, involvement of the pancreatic and/or bile ducts, aortitis and retroperitoneal fibrosis, inflammatory swelling of the lacrimal or salivary glands, and nephropathy. Laboratory changes include hyperproteinemia, increased IgG4 concentration, eosinophilia, and elevated circulating plasmablasts. Presence of any of these symptoms should prompt a differential diagnosis focused on IgG4-RD. Goal: International recommendations for treatment of IgG4-RD were published in 2015, and since then, numerous studies and meta-analyses of new treatment approaches have been published. These indicate that, in 2026, the treatment of choice is monoclonal anti-CD20 antibodies, rituximab or obinutuzumab, or alternatively, the anti-CD19 antibody inebilizumab. Rituximab achieves a significantly higher number of treatment responses and has fewer side effects than the previously used prednisone, whether in monotherapy or in combination with oral immunosuppressants. However, even after rituximab treatment, the rate of early relapses is around 16–20%. Therefore, maintenance therapy with rituximab is recommended. Another approach to achieving a longer-lasting treatment response is the combination of rituximab with cyclophosphamide. In 2025, the anti-CD19 monoclonal antibody inebilizumab was approved in the United States and Europe for the treatment of IgG4-RD. It targets a broader range of B cells than rituximab and induces a longer-lasting therapeutic response. The efficacy of other drugs (obexelimab, abatacept, daratumumab, dupilumab, and others) is documented through case reports and small patient series or phase II clinical trials, and we are awaiting the results of phase III registration studies. Conclusion: Anti-CD20 and anti-CD19 antibodies represent the treatment of choice for IgG4-RD. They achieve a high number of complete treatment responses; however, the treatment does not end there, as it is necessary to prevent disease relapses, which are common without maintenance therapy.
Keywords:
rituximab – inebilizumab – obinutuzumab – IgG4-related disease – retroperitoneal fibrosis – aortitis – obexelimab – sialadenitis – Mikulicz syndrome
Sources
1. Alaggio R, Amador C, Anagnostopoulos I et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36 (7): 1720–1748. doi: 10.1038/s41375-022-01620-2.
2. Stone JH, Khosroshahi A, Deshpande V et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012; 64 (10): 3061–3067. doi: 10.1002/art.34593.
3. Adam Z, Adamová Z, Řehák Z et al. IgG4-releated disease. Klin Onkol 2021; 34 (2): 92–102. doi: 10.48095/ccko202192.
4. Wallace ZS, Miles G, Smolkina E et al. Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults. Ann Rheum Dis 2023; 82 (7): 957–962. doi: 10.1136/ard-2023-223950.
5. Hočevar A, Grošelj A, Hawlina G et al. The incidence of IgG4-related disease in slovenia-single-centre experience. Biomedicines 2025; 13 (9): 2281. doi: 10.3390/biomedicines13092281.
6. Akiyama M, Alshehri W, Ishigaki S et al. The immunological pathogenesis of IgG4-related disease categorized by clinical characteristics. Immunol Med 2025; 48 (1): 11–23. doi: 10.1080/25785826.2024.2407224.
7. Stone JR. Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23 (1): 88–94. doi: 10.1097/BOR.0b013e3283412f7c.
8. Stone JH. IgG4-related disease: lessons from the first 20 years. Rheumatology (Oxford) 2025; 64 (Suppl 1): i24–i27. doi: 10.1093/rheumatology/keaf008.
9. Průcha M, Šedivý P, Stadler P et al. Abdominal aortic aneurysm as an IgG4-related disease. Clinical Exp Immunol 2019; 197 (3): 361–365. doi: 10.1111/cei.13307.
10. Nikiphorou E, Galloway J, Fragoulis GE. Overview of IgG4-related aortitis and periaortitis. A decade since their first description. Autoimmun Rev 2020; 19 (12): 102694. doi: 10.1016/j.autrev.2020.102694.
11. Stejskal V, Sokolova T, Sagat J et al. IgG4 plasma cells in hematopathology: beyond IgG4-related disease. J Hematop 2025; 18 (1): 53. doi: 10.1007/s12308-025-00666-2.
12. Nishikori A, Nishimura MF, Fajgenbaum DC et al. Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): factors to differentiate from IgG4-related disease. J Clin Pathol 2025; 79 (1): 43–49. doi: 10.1136/jcp-2023-209280.
13. Wallace ZS, Deshpande V, Mattoo H et al. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 2015; 67 (9): 2466–2475. doi: 10.1002/art.39205.
14. Yamada K, Yamamoto M, Saeki T et al. New clues to the nature of immunoglobulin G4-related disease: a retrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther 2017; 19 (1): 262. doi: 10.1186/s13075-017-1467-x.
15. Lanzillotta M, Vujasinovic M, Löhr JM et al. Update on autoimmune pancreatitis and IgG4-related disease. United European Gastroenterol J 2025; 13 (1): 107–115. doi: 10.1002/ueg2.12738.
16. Kersten R, Trampert DC, Herta T et al. IgG4-related cholangitis – a mimicker of fibrosing and malignant cholangiopathies. J Hepatol 2023; 79 (6): 1502–1523. doi: 10.1016/j.jhep.2023.08.005.
17. Tanaka A. IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut Liver 2019; 13 (3): 300–307. doi: 10.5009/gnl18085.
18. Doubková M, Matěj R, Chovancová Z et al. Plicní onemocnění a autoimunitní hemolytická anémie asociovaná s IgG4. Vnitr Lek 2020; 66 (4): 47–52.
19. Chovancová Z, Filipenský P, Rotnáglová S et al. Podtřída imunoglobulinů IgG4 a s ní související patologické stavy aneb jak účinně imitovat nádorové onemocnění. Klin Onkol 2022; 35 (1): 20–31. doi: 10.48095/ccko202220.
20. Peňázová P, Andrašina T, Novotný I et al. IgG4 sklerozující cholangitida – zánět imitující nádor hlavy pankreatu a cholangiokarcinom. Klin Onkol 2019; 32 (2): 143–151. doi: 10.14735/amko2019143.
21. Čermák A, Foukal J, Řehák Z et al. Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months. Klin Onkol 2024; 37 (5): 354–369. doi: 10.48095/ccko2024354.
22. Adam Z, Pour L, Zeman D et al. Vzácné choroby provázené hypergamaglobulinemií a zánětlivými projevy. Praha: Grada Publishing 2022. 336 s.
23. Della-Torre E, Talarico R, Ballarin J et al. Identification of red flags for IgG4-related disease: an international European reference network for rare connective tissue diseases framework. Lancet Rheumatol 2025; 7 (1): e64–e71. doi: 10.1016/S2665-9913 (24) 00192-9.
24. Wallace ZS, Zhang Y, Perugino CA et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis 2019; 78 (3): 406–412. doi: 10.1136/annrheumdis-2018-214603.
25. Lanzillotta M, Culver E, Sharma A et al. Fibrotic phenotype of IgG4-related disease. Lancet Rheumatol 2024; 6 (7): e469–e480. doi: 10.1016/S2665-9913 (23) 00299-0.
26. Chen LY, Mattman A, Seidman MA et al. IgG4-related disease: what a hematologist needs to know. Haematologica 2019; 104 (3): 444–455. doi: 10.3324/haematol.2018.205526.
27. Khosroshahi A, Wallace ZS, Crowe JL et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015; 67 (7): 1688–1699. doi: 10.1002/art.39132.
28. Wang L, Chu X, Ma Y et al. A comparative analysis of serum IgG4 levels in patients with IgG4-related disease and other disorders. Am J Med Sci 2017; 354 (3): 252–256. doi: 10.1016/j.amjms.2017.05.009.
29. Wallace ZS, Mattoo H, Carruthers M et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 2015; 74 (1): 190–195. doi: 10.1136/annrheumdis-2014-205233.
30. Zhang J, Chen H, Ma Y et al. Characterizing IgG4-related disease with 18F-FDG PET/CT: a prospective cohort study. Eur J Nucl Med Mol Imaging 2014; 41 (8): 1624–1634. doi: 10.1007/s00259-014-2729-3.
31. Tang CY, Chua WM, Cheng LT et al. 18F-FDG PET/CT manifestations of IgG4-related disease. Br J Radiol 2021; 94 (1124): 20210105. doi: 10.1259/bjr.20210105.
32. Luo Y, Pan Q, Yang H et al. Fibroblast activation protein-targeted PET/CT with 68Ga-FAPI for imaging IgG4-related disease: comparison to 18F-FDG PET/CT. J Nucl Med 2021; 62 (2): 266–271. doi: 10.2967/jnumed.120.244723.
33. Liu S, Pan Q, Zhang H et al. Differences in fibroinflammatory activity shown on 68Ga-FAPI-04 and 18F-FDG PET/CT in the two subtypes of IgG4-related disease. J Nucl Med 2025; 66 (4): 634–640. doi: 10.2967/jnumed.124.268943.
34. Schmidkonz C, Rauber S, Atzinger A et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis 2020; 79 (11): 1485–1491. doi: 10.1136/annrheumdis-2020-217408.
35. Umehara H, Okazaki K, Masaki Y et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-rd), 2011. Mod Rheumatol 2012; 22 (1): 21–30. doi: 10.1007/s10165-011-0571-z.
36. Umehara H, Okazaki K, Kawa S et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-rd. Mod Rheumatol 2021; 31 (3): 529–533. doi: 10.1080/14397595.2020.1859710.
37. Umehara H, Okazaki K, Nakamura T et al. Current approach to the diagnosis of IgG4-related disease – combination of comprehensive diagnostic and organ-specific criteria. Mod Rheumatol 2017; 27 (3): 381–391. doi: 10.1080/14397595.2017.1290911.
38. Wallace ZS, Naden RP, Chari S et al. The 2019 american college of rheumatology/european league against rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 2020; 79 (1): 77–87. doi: 10.1136/annrheumdis-2019-216561.
39. Wallace ZS, Naden RP, Chari S et al. The 2019 american college of rheumatology/european league against rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 2020; 72 (1): 7–19. doi: 10.1002/art.41120.
40. Ren H, Mori N, Sato S et al. American college of rheumatology and the european league against rheumatism classification criteria for IgG4-related disease: an update for radiologists. Jpn J Radiol 2022; 40 (9): 876–893. doi: 10.1007/s11604-022-01282-1.
41. Martínez Calabuig P, Fragío Gil JJ, González Mazarío R et al. IgG4-related disease: effectiveness evaluation through umehara-okazaki 2011 and ACR/EULAR 2019 diagnostic criteria. Med Clin (Barc) 2024; 163 (5): 217–223. doi: 10.1016/j.medcli.2024.03.026.
42. Vikse J, Midtvedt Ø, Fevang BS et al. Differential sensitivity of the 2020 revised comprehensive diagnostic criteria and the 2019 ACR/EULAR classification criteria across IgG4-related disease phenotypes: results from a Norwegian cohort. Arthritis Res Ther 2023; 25 (1): 163. doi: 10.1186/s13075-023-03155-y.
43. Lopez-Gomez M, Moya-Alvarado P, Park HS et al. Comparative analysis of classification criteria in IgG4-related disease and evaluating diagnostic accuracy from a retrospective cohort in clinical practice. Diagnostics (Basel) 2024; 14 (22): 2583. doi: 10.3390/diagnostics14222583.
44. Rajnochová-Bloudíčková S. IgG4-asociované onemocnění ledvin. AVN 2023; 29 (4): 121–124.
45. Mizushima I, Morikage N, Ito E et al. Validation of the diagnostic criteria for IgG4-related periaortitis/periarteritis and retroperitoneal fibrosis (IgG4pa/RPF) 2018, and proposal of a revised 2023 version for IgG4-related cardiovascular/retroperitoneal disease. Circ J 2024; 88 (10): 1679–1688. doi: 10.1253/circj.CJ-24-0026.
46. Saeki T, Kawano M, Nagasawa T et al. Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4--RKD) 2011, and proposal of a new 2020 version. Clin Exp Nephrol 2021; 25 (2): 99–109. doi: 10.1007/s10157-020-01993-7.
47. Löhr JM, Beuers U, Vujasinovic M et al. European guideline on IgG4-related digestive disease – UEG and SGF evidence-based recommendations. United European Gastroenterol J 2020; 8 (6): 637–666. doi: 10.1177/2050640620934911.
48. Naitoh I, Nakazawa T. Classification and diagnostic criteria for IgG4-related sclerosing cholangitis. Gut Liver 2022; 16 (1): 28–36. doi: 10.5009/gnl210116.
49. Takahira M, Goto H, Azumi A. The 2023 revised diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Ophthalmol 2024; 68 (4): 293–301. doi: 10.1007/s10384-024-01072-4.
50. Bakshi N, Aggarwal A, Dhawan S et al. Assessing IgG4-related ophthalmic disease and its mimics: a comparison of ACR/EULAR, organ-specific and revised comprehensive diagnostic criteria. J Clin Pathol 2025; 78 (8): 554–561. doi: 10.1136/jcp-2024-209552.
51. Czarnywojtek A, Agaimy A, Pietrończyk K et al. IgG4--related disease: an update on pathology and diagnostic criteria with a focus on salivary gland manifestations. Virchows Arch 2024; 484 (3): 381–399. doi: 10.1007/s00428-024-03757-0.
52. Takeshima K, Li Y, Kakudo K et al. Proposal of diagnostic criteria for IgG4-related thyroid disease. Endocr J 2021; 68 (1): 1–6. doi: 10.1507/endocrj.EJ20-0557.
53. Kanda M, Nagahata K, Moriyama M et al. The 2023 revised diagnostic criteria for IgG4-related dacryoadenitis and sialadenitis. Mod Rheumatol 2025; 35 (3): 542–547. doi: 10.1093/mr/roae096.
54. Matsui S. IgG4-related respiratory disease. Mod Rheumatol 2019; 29 (2): 251–256. doi: 10.1080/14397595.2018.1548089.
55. Handa T, Matsui S, Yamamoto H et al. The 2022 revised diagnostic criteria for IgG4-related respiratory diseases. Respir Investig 2023; 61 (6): 755–759. doi: 10.1016/j.resinv.2023.06.009.
56. Saitakis G, Chwalisz BK. The neurology of IgG4-related disease. J Neurol Sci 2021; 424 : 117420. doi: 10.1016/j.jns.2021.117420.
57. Terrim S, Mahler JV, Filho FVM et al. Clinical presentation, investigation findings, and outcomes of IgG4-related pachymeningitis: a systematic review. JAMA Neurol 2025; 82 (2): 193–199. doi: 10.1001/jamaneurol.2024.3947.
58. Ng YZ, Bowen S, Phillips J et al. Neurological manifestations of immunoglobulin IgG4 related disease: a systematic review of 393 cases. J Neurol Neurosurg Psychiatry 2025; 96 (11): 1109–1116. doi: 10.1136/jnnp-2025-336230.
59. Hasegawa S, Mine S, Hagiwara S. IgG4-related disease combined with autoimmune hemolytic anemia and steroid-responsive transient hypercalcemia. Clin Med Insights Case Rep 2015; 8 : 51–55. doi: 10.4137/CCRep.S25553.
60. Noguchi S, Yatera K, Jinbo M et al. IgG4-related lung disease associated with autoimmune hemolytic anemia: a case report and a literature review. Intern Med 2016; 55 (17): 2469–2474. doi: 10.2169/internalmedicine.55.6499.
61. Maslinska M, Kostyra-Grabczak K. Immunoglobulin G4 in primary Sjögren’s syndrome and IgG4-related disease – connections and dissimilarities. Front Immunol 2024; 15 : 1376723. doi: 10.3389/fimmu.2024.1376723.
62. Otani Y, Shimura T, Nogaki T et al. Differentiation between IgG4-related Mikulicz disease and Sjögren’s syndrome: a review case report and literature review. Medicine (Baltimore) 2022; 101 (52): e32617. doi: 10.1097/MD.0000000000032617.
63. Bashir F, Bashir M, Rafiq M et al. Symmetrical polyarthritis in IgG4-related sialadenitis: a diagnostic challenge with seronegative rheumatoid arthritis. BMC Rheumatol 2025; 9 (1): 20. doi: 10.1186/s41927-025-00471-5.
64. Martín-Nares E, Delgado-de la Mora J, Martínez--Benítez B et al. Aortitis in rheumatoid arthritis: think on overlapping IgG4-related disease: scleritis and aortitis in early rheumatoid arthritis. J Clin Rheumatol 2021; 27 (8S): S863. doi: 10.1097/RHU.0000000000001770.
65. Kotani H, Ohtsuka T, Okada S et al. A case of IgG4-related disease presented with kimura disease-like skin eruption, rheumatoid arthritis-like abnormality and interstitial pneumonia. Clin Exp Dermatol 2020; 45 (6): 733–734. doi: 10.1111/ced.14222.
66. Omar D, Chen Y, Cong Y et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. Rheumatology (Oxford) 2020; 59 (4): 718–726. doi: 10.1093/rheumatology/kez380.
67. Akiyama M, Takeuchi T. IgG4-related disease: beyond glucocorticoids. Drugs Aging 2018; 35 (4): 275–287. doi: 10.1007/s40266-018-0534-6.
68. Alsalamah NI, Alhrabi B, Alhumaily N et al. Efficacy and safety of glucocorticoid monotherapy versus the combination of glucocorticoid and immunosuppressive agents for immunoglobulin G4-related disease: a systematic review and meta-analysis. Cureus 2023; 15 (10): e47099. doi: 10.7759/cureus.47099.
69. Yamamoto M, Yajima H, Takahashi H et al. Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis: results from the SMART database. Mod Rheumatol 2015; 25 (2): 199–204. doi: 10.3109/14397595.2014.950036.
70. Eroglu E, Sipahioglu MH, Senel S et al. Successful treatment of tubulointerstitial nephritis in immunoglobulin G4-related disease with rituximab: a case report. World J Clin Cases 2019; 7 (16): 2309–2315. doi: 10.12998/wjcc.v7.i16.2309.
71. Carruthers MN, Topazian MD, Khosroshahi A et al. Rituximab for IgG4-related disease: a prospective, open--label trial. Ann Rheum Dis 2015; 74 (6): 1171–1177. doi: 10.1136/annrheumdis-2014-206605.
72. Ebbo M, Grados A, Samson M et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a french nationwide study of thirty-three patients. PLoS One 2017; 12 (9): e0183844. doi: 10.1371/journal.pone.0183844.
73. Liu Y, Jin K, Yang Y et al. Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta--analysis. Eur J Intern Med 2024; 127 : 63–73. doi: 10.1016/j.ejim.2024.06.006.
74. Majumder S, Mohapatra S, Lennon RJ et al. Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease. Clin Gastroenterol Hepatol 2018; 16 (12): 1947–1953. doi: 10.1016/j.cgh.2018.02.049.
75. Detiger SE, Karim AF, Verdijk RM et al. The treatment outcomes in IgG4-related orbital disease: a systematic review of the literature. Acta Ophthalmol 2019; 97 (5): 451–459. doi: 10.1111/aos.14048.
76. Lanzillotta M, Della-Torre E, Wallace ZS et al. Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: a systematic review and meta-analysis. Pancreatology 2021; 21 (7): 1395–1401. doi: 10.1016/j.pan.2021.06.009.
77. Wallwork R, Wallace Z, Perugino C et al. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine (Baltimore) 2018; 97 (42): e12631. doi: 10.1097/MD.0000000000012631.
78. Boyeva V, Alabsi H, Seidman MA et al. Use of rituximab in idiopathic retroperitoneal fibrosis. BMC Rheumatol 2020; 4 : 40. doi: 10.1186/s41927-020-00140-9.
79. Orozco-Gálvez O, Fernández-Codina A, Lanzillotta M et al. Development of an algorithm for IgG4-related disease management. Autoimmun Rev 2023; 22 (3): 103273. doi: 10.1016/j.autrev.2023.103273.
80. Dong Y, Zhang L, Nong L et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric castleman disease. Ann Hematol 2018; 97 (9): 1641–1647. doi: 10.1007/s00277-018-3347-0.
81. Benad M, Koschel D, Herrmann K et al. Effects of cyclophosphamide and rituximab in patients with connective tissue diseases with severe interstitial lung disease. Clin Exp Rheumatol 2022; 40 (3): 483–488. doi: 10.55563/clinexprheumatol/o5t1f7.
82. San S, Lin CD, Tsai ST et al. Immunoglobulin G4-related disease presented as recurrent otitis media and mixed hearing loss treated with cyclophosphamide and rituximab: a case report. Arch Rheumatol 2018; 34 (2): 233–237. doi: 10.5606/ArchRheumatol.2019.7178.
83. Quattrocchio G, Barreca A, Demarchi A et al. IgG4--related kidney disease: the effects of a rituximab-based immunosuppressive therapy. Oncotarget 2018; 9 (30): 21337–21347. doi: 10.18632/oncotarget.25095.
84. Adam Z, Fojtík Z, Řehák Z et al. Polyclonal hypergammaglobulinemia, infiltration of salivary glands, lymfadenopathy and kidney damage – Mikulicz’s disease, Sjögren syndrom or Castleman disease? Case report and overview of diferencial diagnosis and treatment. Kli Onkol 2025; 38 (6): 447-463. doi: 10.48095/ccko2025447.
85. Della-Torre E, Conti A, Berti A et al. Rituximab hypersensitivity in IgG4-related disease: successful desensitization in a patient with IgG4 rheumatoid factor. Int J Rheum Dis 2017; 20 (2): 276–279. doi: 10.1111/1756-185X.13021.
86. Lanzillotta M, Mapelli P, Dagna L et al. B-cell depletion with obinutuzumab for the treatment of IgG4-related disease. Eur J Intern Med 2023; 116 : 155–156. doi: 10.1016/j.ejim.2023.07.019.
87. Sun H, Zeng X, Li Y et al. Successful remission induction of IgG4-related ophthalmic disease by obinutuzumab therapy: a retrospective study of 8 patients. Eye (Lond) 2024; 38 (4): 723–729. doi: 10.1038/s41433-023-02758-8.
88. Ginthör NE, Artinger K, Pollheimer MJ et al. Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab. Clin Kidney J 2021; 15 (3): 564–566. doi: 10.1093/ckj/sfab250.
89. Stone JH, Khosroshahi A, Zhang W et al. Inebilizumab for treatment of IgG4-related disease. N Engl J Med 2025; 392 (12): 1168–1177. doi: 10.1056/NEJMoa2409712.
90. Nowak RJ, Benatar M, Ciafaloni E et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med 2025; 392 (23): 2309–2320. doi: 10.1056/NEJMoa2501561.
91. Nie T, Blair HA. Inebilizumab: a review in neuromyelitis optica spectrum disorder. CNS Drugs 2022; 36 (10): 1133–1141. doi: 10.1007/s40263-022-00949-7.
92. Herta T, Schröder M, Geisel D et al. Management of IgG4-related cholangitis: diagnosis, therapy, and long--term surveillance. Gastroenterol Rep (Oxf) 2025; 13: goaf032. doi: 10.1093/gastro/goaf032.
93. Chu SY, Vostiar I, Karki S et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and fcgammariib with FC-engineered antibodies. Mol Immunol 2008; 45 (15): 3926–3933. doi: 10.1016/j.molimm.2008.06.027.
94. Perugino CA, Wallace ZS, Zack DJ et al. Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial. Lancet Rheumatol 2023; 5 (8): e442–e450. doi: 10.1016/S2665-9913 (23) 00157-1.
95. Poo SX, Pepper RJ, Onwordi L et al. Sirolimus use in patients with subglottic stenosis in the context of granulomatosis with polyangiitis (GPA), suspected GPA, and immunoglobulin g. Scand J Rheumatol 2021; 50 (1): 52–57. doi: 10.1080/03009742.2020.1777324.
96. Matza MA, Perugino CA, Harvey L et al. Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study. Lancet Rheumatol 2022; 4 (2): e105–e112. doi: 10.1016/S2665-9913 (21) 00359-3.
97. Peng Y, Zhang W. Abatacept for IgG4-related disease: therapeutic prospects according to disease immunophenotype. Lancet Rheumatol 2022; 4 (2): e75–e76. doi: 10.1016/S2665-9913 (21) 00390-8.
98. Yamamoto M, Takahashi H, Takano K et al. Efficacy of abatacept for IgG4-related disease over 8 months. Ann Rheum Dis 2016; 75 (8): 1576–1578. doi: 10.1136/annrheumdis-2016-209368.
99. Kanda M, Kamekura R, Sugawara M et al. IgG4-related disease administered dupilumab: case series and review of the literature. RMD Open 2023; 9 (1): e003026. doi: 10.1136/rmdopen-2023-003026.
100. Della-Torre E, Lanzillotta M, Yacoub MR. Dupilumab as a. Ann Rheum Dis 2022; 81 (2): e24. doi: 10.1136/annrheumdis-2020-216945.
101. Yamamoto M, Yoshikawa N, Tanaka H. Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis. Ann Rheum Dis 2022; 81 (3): e50. doi: 10.1136/annrheumdis-2020-217076.
102. Beck TC, Plante J, Robinson I et al. Immunoglobulin g4-related disease-associated dermatitis with pruritus: a positive response to dupilumab. Life (Basel) 2023; 13 (3): 833. doi: 10.3390/life13030833.
103. Hoy SM. Dupilumab: a review in chronic rhinosinusitis with nasal polyps. Drugs 2020; 80 (7): 711–717. doi: 10.1007/s40265-020-01298-9.
104. Coulomb D, Szablewski V, Robert N et al. A case of refractory IgG4-related disease successfully treated with daratumumab and lenalidomide. Rheumatology (Oxford) 2025; 64 (2): 895–897. doi: 10.1093/rheumatology/keae448.
105. González-García A, Starita-Fajardo G, Lucena López D et al. New developments in the treatment of IgG4-related disease: a comprehensive clinical approach. J Clin Med 2025; 14 (19): 6774. doi: 10.3390/jcm14196774.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2026 Issue 4
Most read in this issue
- Treatment of Erdheim-Chester disease from the perspective in 2026
- Evaluation of ice ball size as a function of freezing intensity through computed tomography scans during cryoablation procedures
- Dlouhá cesta k RAS (on) inhibitoru
- IgG4-related disease – treatment with anti-CD20, anti-CD19 antibodies, and other new drugs